ArticleEuropean journal of pharmacology2008
Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration.
Article in European journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Escalation of intravenous fentanyl self-administration and assessment of withdrawal behavior in male and female mice.Psychopharmacology · 2025Article
- Oral fentanyl consumption and withdrawal impairs fear extinction learning and enhances basolateral amygdala principal neuron excitatory-inhibitory balance in male and female mice.Addiction neuroscience · 2024Article
- Biodistribution of Agmatine to Brain and Spinal Cord after Systemic Delivery.The Journal of pharmacology and experimental therapeutics · 2023Article
- Transcriptomic profiling of reward and sensory brain areas in perinatal fentanyl exposed juvenile mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- IGF-1 Microinjection in the Prefrontal Cortex Attenuates Fentanyl-Seeking Behavior in Mice.The international journal of neuropsychopharmacology · 2023Article
- Long-term reversal of chronic pain behavior in rodents through elevation of spinal agmatine.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Stress reveals a specific behavioral phenotype for opioid abuse susceptibility.Journal of the experimental analysis of behavior · 2022Article
- Environmental Enrichment Mitigates the Long-Lasting Sequelae of Perinatal Fentanyl Exposure in Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- Effects of imidazoline agents in a rat conditioned place preference model of addiction.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Perinatal Fentanyl Exposure Leads to Long-Lasting Impairments in Somatosensory Circuit Function and Behavior.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Aversion-resistant fentanyl self-administration in mice.Psychopharmacology · 2021Article
- Enduring consequences of perinatal fentanyl exposure in mice.Addiction biology · 2021Article
- The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes.Drug and alcohol dependence · 2018Article
- Effect of anchoring 4-anilidopiperidines to opioid peptides.Bioorganic & medicinal chemistry letters · 2013Article
- Article
- Focused review: agmatine in fermented foods.Frontiers in microbiology · 2012Article
- OCT2 and MATE1 provide bidirectional agmatine transport.Molecular pharmaceutics · 2011Article
- Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance.The Journal of pharmacology and experimental therapeutics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The decarboxylation product of arginine, agmatine, has effectively reduced or prevented opioid-induced tolerance and dependence when given either systemically (intraperitoneally or subcutaneously) or centrally (intrathecally or intracerebroventricularly). Systemically administered agmatine also reduces the escalation phase of intravenous fentanyl self-administration in rats. The present study assessed whether centrally (intracerebroventricular, i.c.v.) delivered agmatine could prevent the development of fentanyl self-administration in mice. Mice were trained to respond under a fixed-ratio 1 (FR1) schedule for either fentanyl (0.7 microg/70 microl, p.o.) or food reinforcement. Agmatine (10 nmol/5 microl), injected i.c.v. 12-14 h before the first session and every other evening (12-14 h before session) for 2 weeks, completely attenuated oral fentanyl self-administration (but not food-maintained responding) compared to saline-injected controls. When agmatine was administered after fentanyl self-administration had been established (day 8) it had no attenuating effects on bar pressing. This dose of agmatine does not decrease locomotor activity as assessed by rotarod. The present findings significantly extend the previous observation that agmatine prevents opioid-maintained behavior to a chronic model of oral fentanyl self-administration as well as identifying a supraspinal site of action for agmatine inhibition of drug addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.